Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283815 | 1.00 | LMNA (0.38) | LMNASMN1; SMN2POLBUSP2GAA | |
| SCHEMBL18896855 | 0.81 | MEN1 (0.36) | LMNASMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL226255 | 0.79 | HTR2C (0.40) | LMNASMN1; SMN2POLBGAAHPGD | |
| SCHEMBL3662388 | 0.79 | HTR2C (0.40) | LMNASMN1; SMN2POLBGAAHPGD | |
| SCHEMBL226527 | 0.79 | HTR2C (0.40) | LMNASMN1; SMN2POLBGAAHPGD | |
| SCHEMBL482800 | 0.79 | CNR2 (0.45) | GAAKMT2ACNR2 | |
| SCHEMBL283318 | 0.79 | CNR2 (0.49) | GAAKMT2AMEN1CNR2 | |
| SCHEMBL4915454 | 0.78 | KMT2A (0.41) | LMNAPOLBGAAKMT2AMEN1 | |
| SCHEMBL7494216 | 0.78 | ALDH1A1 (0.40) | LMNASMN1; SMN2POLBUSP2GAA | |
| SCHEMBL4915463 | 0.78 | KMT2A (0.41) | LMNAPOLBGAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193713-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| EP-2851366-A1 | Compounds as cannabinoid receptor ligands | Abbvie Inc. (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8492371-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2331516-B1 | IMINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LAB (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-8173687-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010111572-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2219629-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2010019547-A1 | IMINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041720-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009048936-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | LMNA 2952/4885SMN1; SMN2 3098/4885POLB 4758/4885 |
| US-20100041720-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | LMNA 3300/4885SMN1; SMN2 3351/4885POLB 4710/4885 |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | LMNA 2882/4885SMN1; SMN2 3467/4885POLB 4785/4885 |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | LMNA 3477/4885SMN1; SMN2 3278/4885POLB 4689/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | LMNA 2882/4885SMN1; SMN2 3467/4885POLB 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.